Secondary Progressive Multiple Sclerosis clinical trials

Explore recruiting secondary progressive multiple sclerosis clinical trials.

Recruiting secondary progressive multiple sclerosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Secondary Progressive Multiple Sclerosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis

Germany, Bulgaria, Netherlands, Sweden, Portugal, Croatia +15 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the Treatment of Patients with Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse

Greece, Spain, Poland, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis

Italy, Netherlands, Belgium, Bulgaria, Spain, Hungary +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Open-Label, Randomized, Multicenter Study of KYV101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis (KYSA-7)

Germany, Italy, Belgium, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Denmark, Slovenia, Netherlands, Portugal, Ireland, Sweden +19 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Secondary Progressive Multiple Sclerosis trials by city

Secondary Progressive Multiple Sclerosis in Toronto Secondary Progressive Multiple Sclerosis in Vancouver Secondary Progressive Multiple Sclerosis in Montreal Secondary Progressive Multiple Sclerosis in Calgary Secondary Progressive Multiple Sclerosis in Edmonton Secondary Progressive Multiple Sclerosis in Ottawa Secondary Progressive Multiple Sclerosis in Winnipeg Secondary Progressive Multiple Sclerosis in Quebec City Secondary Progressive Multiple Sclerosis in Hamilton Secondary Progressive Multiple Sclerosis in Kitchener Secondary Progressive Multiple Sclerosis in London Secondary Progressive Multiple Sclerosis in Halifax Secondary Progressive Multiple Sclerosis in New York Secondary Progressive Multiple Sclerosis in Los Angeles Secondary Progressive Multiple Sclerosis in Chicago Secondary Progressive Multiple Sclerosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease